Name | TAK-779 |
Description | TAK-779 (Takeda 779) is an antagonist of chemokine receptor 5 (CCR5), CCR2b, and CXC chemokine receptor 3 (CXCR3). |
In vitro | TAK-779 (250 mg/animal per day) inhibits ovalbumin-induced increases in CCR5, CXCR3, IFN-γ, and TNF-α expression in mouse lung, as well as the number of total cells, lymphocytes, and eosinophils in bronchoalveolar lavage fluid (BALF), in a mouse model of asthma[1]. |
In vivo | TAK-779 increases intestinal allograft survival in a rat model of small intestine transplantation when administered at a dose of 10 mg/kg per day[2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : 16.66 mg/mL (31.37 mM), Sonication is recommended. DMSO : 25 mg/mL (47.07 mM), Sonication is recommended.
|
Keywords | Takeda-779 | Takeda779 | TAK-779 | TAK779 | TAK 779 | Inhibitor | inhibit | Human immunodeficiency virus | HIVProtease | HIV Protease | HIV | CXCR | CXC chemokine receptors | CCR2 | CCR | CC chemokine receptor |
Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Kaempferol | Dolutegravir intermediate-1 | Tannic acid | Dextran sulfate sodium salt (MW 4500-5500) | Lamivudine | Chloroquine phosphate | Valproic Acid | Decanedioic acid | Tenofovir |
Related Compound Libraries | Bioactive Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | Anti-Viral Compound Library | Inhibitor Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | GPCR Compound Library | Anti-COVID-19 Compound Library | Anti-Cancer Compound Library |